Market Cap 20.98M
Revenue (ttm) 0.00
Net Income (ttm) -79.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 94,900
Avg Vol 549,434
Day's Range N/A - N/A
Shares Out 33.19M
Stochastic %K 7%
Beta 0.59
Analysts Hold
Price Target $0.87

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 629 1376
Address:
2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States
VictorMason
VictorMason Jul. 17 at 3:33 PM
$RLMD at least you can say RLMD isn't 'overbought' Skating up to the edge
0 · Reply
Cashflow62
Cashflow62 Jul. 16 at 2:18 PM
$RLMD Bold prediction here, going to a buck next 30-45 days.
1 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 15 at 12:05 PM
$RLMD Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 By Relmada Therapeutics | July 15, 2025, 8:00 AM
0 · Reply
VictorMason
VictorMason Jul. 11 at 1:23 PM
$RLMD after $600MM spent they just abandon REL-1017? didn't complete the recruitment of vetted candidates for Relight placebo arm do over of the phase 3. But trust these guys to find new projects to develop. No big expense payment coming up, why abandon and not sell it to someone who knows how to control for placebo effect. Watch what Inturisi and Manfrefi do with it, bet Sergio will be involved w a bigger %
1 · Reply
1972Camaro
1972Camaro Jul. 10 at 12:33 PM
$NUVB here are two interesting candidates with insider buying I am watching, $MBRX $RLMD
2 · Reply
Gmebe
Gmebe Jul. 8 at 9:05 PM
$RLMD 14 days left to get compliance. Extension is probably going to be requested id guess as its a bit late to do an RS.
0 · Reply
VictorMason
VictorMason Jul. 3 at 4:02 PM
$RLMD interesting new report, but misleading on some of their 6 critical points. 'Earnings' and revenue going down - they have neither, only losses ($600MM so far to develop the abandoned REL-1017) Insider buying isnt all that much $$, they took millions in cheap stock options. They can always sell the tax losses ($3/ share?) And sell REL1017 phase 3 to someone who knows how to handle a placebo effect https://share.google/seOmgMXD1pM7dxjfx
0 · Reply
RebelWithoutAPause777
RebelWithoutAPause777 Jun. 30 at 11:39 PM
$RLMD COO Paul Kelly just bought 400,000 shares at an average of .67 a share 👀👀👀
3 · Reply
VictorMason
VictorMason Jun. 27 at 5:36 PM
1 · Reply
JunkPost
JunkPost Jun. 26 at 9:24 PM
$RLMD Looks like Low in cash
3 · Reply
Latest News on RLMD
Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:02 PM EDT - 2 months ago

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript


UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 2 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025


Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 24, 2025, 8:00 AM EDT - 3 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data


Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 14, 2025, 7:30 AM EDT - 3 months ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025


VictorMason
VictorMason Jul. 17 at 3:33 PM
$RLMD at least you can say RLMD isn't 'overbought' Skating up to the edge
0 · Reply
Cashflow62
Cashflow62 Jul. 16 at 2:18 PM
$RLMD Bold prediction here, going to a buck next 30-45 days.
1 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 15 at 12:05 PM
$RLMD Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 By Relmada Therapeutics | July 15, 2025, 8:00 AM
0 · Reply
VictorMason
VictorMason Jul. 11 at 1:23 PM
$RLMD after $600MM spent they just abandon REL-1017? didn't complete the recruitment of vetted candidates for Relight placebo arm do over of the phase 3. But trust these guys to find new projects to develop. No big expense payment coming up, why abandon and not sell it to someone who knows how to control for placebo effect. Watch what Inturisi and Manfrefi do with it, bet Sergio will be involved w a bigger %
1 · Reply
1972Camaro
1972Camaro Jul. 10 at 12:33 PM
$NUVB here are two interesting candidates with insider buying I am watching, $MBRX $RLMD
2 · Reply
Gmebe
Gmebe Jul. 8 at 9:05 PM
$RLMD 14 days left to get compliance. Extension is probably going to be requested id guess as its a bit late to do an RS.
0 · Reply
VictorMason
VictorMason Jul. 3 at 4:02 PM
$RLMD interesting new report, but misleading on some of their 6 critical points. 'Earnings' and revenue going down - they have neither, only losses ($600MM so far to develop the abandoned REL-1017) Insider buying isnt all that much $$, they took millions in cheap stock options. They can always sell the tax losses ($3/ share?) And sell REL1017 phase 3 to someone who knows how to handle a placebo effect https://share.google/seOmgMXD1pM7dxjfx
0 · Reply
RebelWithoutAPause777
RebelWithoutAPause777 Jun. 30 at 11:39 PM
$RLMD COO Paul Kelly just bought 400,000 shares at an average of .67 a share 👀👀👀
3 · Reply
VictorMason
VictorMason Jun. 27 at 5:36 PM
1 · Reply
JunkPost
JunkPost Jun. 26 at 9:24 PM
$RLMD Looks like Low in cash
3 · Reply
RebelWithoutAPause777
RebelWithoutAPause777 Jun. 26 at 7:21 PM
$RLMD @Gmebe When are you going to cover your short position? Better now than when $RLMD goes to $2 ++
0 · Reply
PharmaExpert
PharmaExpert Jun. 26 at 7:04 PM
$AKBA, $ADIL, $RLMD, $MEIP, $INDP 🔥🔥🔥🔥🔥
0 · Reply
BAGzEXCITEDzilla1
BAGzEXCITEDzilla1 Jun. 26 at 6:13 PM
Time to buy and hold some $RLMD!
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jun. 26 at 5:58 PM
$RLMD $0.80 micro float 5m new $SONM and $ASTI
1 · Reply
secobabyB
secobabyB Jun. 26 at 3:47 PM
$RLMD on watchlist paying
0 · Reply
VictorMason
VictorMason Jun. 22 at 7:49 PM
0 · Reply
VictorMason
VictorMason Jun. 18 at 9:51 PM
$RLMD old notice: The notification, received on Monday, January 21, 2025, does not immediately affect the company's listing. Relmada has been granted a 180-day compliance period, which concludes on July 21, 2025, to meet the minimum bid price criterion. The company’s stock must close at $1 or higher for at least ten consecutive business days within this timeframe to regain compliance. If Relmada opts for a reverse stock split to address the issue, it must be executed at least ten days before the compliance period ends.
1 · Reply
Gmebe
Gmebe Jun. 13 at 10:46 AM
$RLMD oh dear. And its not even the inevitable reverse split and dilution yet. Dont say you were not warned. Those who do without any due diligence but blindly follow like sheep will be punished.
1 · Reply
teaman60
teaman60 Jun. 12 at 4:32 PM
$RLMD Told u so
1 · Reply
BigBazza
BigBazza Jun. 12 at 4:25 PM
$RLMD where will this dip stop?
0 · Reply
RebelWithoutAPause777
RebelWithoutAPause777 Jun. 11 at 4:24 PM
$RLMD "The end is near" - Probably Tea Man
1 · Reply
teaman60
teaman60 Jun. 10 at 1:40 PM
$RLMD it's gonna crash fast, trust me on this. And no I am not a shorter
2 · Reply